China National Pharmaceutical Group Co., Ltd. Consistency 2025 Revenue 73.416 Billion USD with Net Profit of 1.136 Billion Yuan

MaticHoleFiller · 2026-03-18T03:11:24+00:00

China National Pharmaceutical Holdings released its 2025 performance flash report, with total operating revenue of 73.416 billion yuan, down 1.29% year-over-year. However, profit grew significantly, with net profit attributable to shareholders of 11.36 billion yuan, up 76.80% year-over-year. The profit growth was primarily driven by a reduction in asset impairment reserves and store adjustments. Additionally, the distribution segment showed steady growth, while the retail segment's revenue declined, though operating quality improved.

MaticHoleFiller

2026-03-18 03:11:24

Abstract generation in progress

Guancha.com News: On March 18, China National Pharmaceutical Group Holding Co., Ltd. released an overseas regulatory announcement, disclosing the 2025 performance forecast for China National Pharmaceutical Group’s consistent pharmaceutical subsidiary.

According to the announcement, during the reporting period, China National Pharmaceutical Consistent achieved operating revenue of 73.416 billion yuan, a decrease of 1.29% year-on-year. Profit indicators performed well, with operating profit of 1.513 billion yuan, up 163.80% year-on-year; total profit of 1.509 billion yuan, up 162.22%; net profit attributable to shareholders of the listed company of 1.136 billion yuan, up 76.80%. Basic earnings per share increased by 77.39% year-on-year, and the weighted average return on net assets rose by 2.59 percentage points.

The significant profit growth mainly stems from two factors. First, the impairment provisions for goodwill and intangible assets decreased by 686 million yuan year-on-year. Second, store adjustments led to a reduction in rigid costs such as labor and rent.

In terms of segments, the distribution segment, as the core of operations, achieved operating revenue of 53.321 billion yuan during the period, up 0.64% year-on-year; net profit of 949 million yuan, up 2.94%. This segment maintained steady growth by optimizing resource allocation and product mix, actively expanding the market.

For the retail segment, China National Pharmaceutical Holdings Co., Ltd. Guda Pharmacy achieved operating revenue of 20.981 billion yuan, down 6.16% year-on-year; net loss of 217 million yuan, an 80.36% increase in loss. Excluding impairment of goodwill and intangible assets, Guda Pharmacy realized a net profit of 60 million yuan, up 139.28%. This segment improved operational quality through strengthening procurement systems, developing own brands, optimizing product structure, and strategically adjusting store layouts.

Disclaimer: The content and data in this article are compiled by Guancha based on publicly available information and do not constitute investment advice. Please verify before use.

Massive information, precise analysis, all on Sina Finance APP

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.